Collplant Intangible Assets from 2010 to 2026
| CLGN Stock | USD 0.72 0.04 5.88% |
Intangible Assets | First Reported 2012-09-30 | Previous Quarter 102 K | Current Value 88 K | Quarterly Volatility 553.7 K |
Check Collplant Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Collplant Biotechnologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 596.9 K, Interest Expense of 33.2 K or Selling General Administrative of 3.9 M, as well as many indicators such as Price To Sales Ratio of 88.24, Dividend Yield of 0.0 or PTB Ratio of 4.63. Collplant financial statements analysis is a perfect complement when working with Collplant Biotechnologies Valuation or Volatility modules.
Collplant | Intangible Assets | Build AI portfolio with Collplant Stock |
Evaluating Collplant Biotechnologies's Intangible Assets across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Collplant Biotechnologies's fundamental strength.
Latest Collplant Biotechnologies' Intangible Assets Growth Pattern
Below is the plot of the Intangible Assets of Collplant Biotechnologies over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Collplant Biotechnologies' Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Collplant Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
| Intangible Assets | 10 Years Trend |
|
Intangible Assets |
| Timeline |
Collplant Intangible Assets Regression Statistics
| Arithmetic Mean | 304,196 | |
| Geometric Mean | 254,440 | |
| Coefficient Of Variation | 52.44 | |
| Mean Deviation | 145,020 | |
| Median | 338,006 | |
| Standard Deviation | 159,506 | |
| Sample Variance | 25.4B | |
| Range | 416.5K | |
| R-Value | (0.88) | |
| Mean Square Error | 6.3B | |
| R-Squared | 0.77 | |
| Slope | (27,709) | |
| Total Sum of Squares | 407.1B |
Collplant Intangible Assets History
About Collplant Biotechnologies Financial Statements
Collplant Biotechnologies investors utilize fundamental indicators, such as Intangible Assets, to predict how Collplant Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Intangible Assets | 117.9 K | 112 K |
Pair Trading with Collplant Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collplant Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Collplant Stock
Moving against Collplant Stock
| 0.7 | EQ | Equillium | PairCorr |
| 0.62 | DRTS | Alpha Tau Medical | PairCorr |
| 0.49 | VERA | Vera Therapeutics Sell-off Trend | PairCorr |
| 0.46 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.45 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Collplant Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collplant Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collplant Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collplant Biotechnologies to buy it.
The correlation of Collplant Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collplant Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collplant Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collplant Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Collplant Biotechnologies Correlation against competitors. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could Collplant diversify its offerings? Factors like these will boost the valuation of Collplant Biotechnologies. Projected growth potential of Collplant fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Collplant Biotechnologies data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.10) | Revenue Per Share | Quarterly Revenue Growth 18.25 | Return On Assets | Return On Equity |
Investors evaluate Collplant Biotechnologies using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Collplant Biotechnologies' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Collplant Biotechnologies' market price to deviate significantly from intrinsic value.
It's important to distinguish between Collplant Biotechnologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collplant Biotechnologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Collplant Biotechnologies' market price signifies the transaction level at which participants voluntarily complete trades.